Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
160
resultados
Última actualización
04/09/2025 [07:30:00]
Resultados 75 a 100 de 160
Resumen de: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Resumen de: CN120072056A
The invention provides application of intestinal flora as a marker in preparation of a product for evaluating the treatment effect of inflammatory bowel diseases. The feasibility of predicting the curative effect of the medicine for treating the inflammatory bowel disease patient by using the microbial spectrum can accurately discriminate the patient needing to optimize the treatment scheme in the early stage of the disease, so that the prognosis condition of the patient is remarkably improved. Meanwhile, the invention provides a construction method of an intestinal flora biomarker prediction model, accurate prediction of the ineffective condition of drug treatment is realized through the combination of faecobacteria prausnitzii, Blauratia massiensis and coma faecalis, and the potential of the intestinal flora biomarker prediction model as a new tool for early recognition of a patient possibly needing optimized treatment is highlighted.
Resumen de: CN120041371A
The invention relates to the technical field of cell biology, in particular to a construction method and application of intestinal organs for children with Crohn's disease, the intestinal organs for children with Crohn's disease are successfully constructed by utilizing intestinal tissues from children with Crohn's disease, and the intestinal organs have various characteristic cells of the intestinal tissues; besides, immune cells are extracted from peripheral blood of a child patient homologous with intestinal tissues, a co-culture system is established with the organ-like model, the intestinal immune microenvironment of the child patient suffering from the Crohn's disease can be reproduced, and the system provides a new model for related mechanism exploration and drug screening of the child Crohn's disease.
Resumen de: CN120047411A
The invention provides a method for assisting in identifying ulcerative colitis inflammatory activity levels based on dynamic graph multi-instance learning. The method comprises the steps of data acquisition, data preprocessing, dynamic graph multi-instance learning model construction of inflammatory activity level diagnosis and model evaluation. The data acquisition mainly comprises the steps of collecting pathological images of a patient with ulcerative colitis, digitalizing the pathological images through a digital scanner, excluding a part of pathological images containing problems such as blurring, fading and abnormal staining, and finally determining a grading label of each pathological image by a deep gastrointestinal pathology expert. The data preprocessing mainly comprises the steps of processing a digital pathological image, converting the digital pathological image into image blocks, then extracting features from each image block by using a visual basic model, and finally constructing a dynamic graph multi-instance learning model for training. According to the method, exploration of the internal relation of the image blocks input to the WSI is promoted, and the prediction effect of the model is improved.
Resumen de: PH12022550223A1
Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.
Resumen de: CN120026084A
The invention belongs to the technical field of biological medicine, and particularly relates to a target spot for photodynamic treatment of ulcerative colitis and application of the target spot. According to the invention, LD4 is used for treating ulcerative colitis for proteomics research, then a Lasso machine learning algorithm is used for screening key targets, and it is found that the expression quantity of EPHX2 protein has significant correlation with ulcerative colitis, so that the EPHX2 protein can be used as a biomarker of ulcerative colitis. According to the application disclosed by the invention, the Pearson correlation calculation principle is used for analysis to find that the EPHX2 protein and the memory B cells have extremely remarkable correlation, and the infiltration amount of various immune cells is controlled by inhibiting the expression of the EPHX2 protein, particularly the abnormal increase of the memory B cells in the intestinal inflammation period is inhibited, so that the inflammation is promoted to gradually subside. Through analysis of a working characteristic curve of a subject, the kit is found to have excellent clinical sensitivity and specificity. The invention provides a new target for researching a novel medicine for treating ulcerative colitis, also provides a detection target for diagnosing ulcerative colitis, and has a good application prospect.
Resumen de: EP4285988A2
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Resumen de: CN120015247A
The invention belongs to the technical field of medical auxiliary diagnosis, and discloses an ulcerative colitis virtual biopsy method and system based on a multi-modal image, and the method comprises the steps: building an ulcerative colitis medical image database; constructing a prediction data set according to the extracted quantitative features and the pathological grades of the ulcerative colitis patients; based on the prediction data set, constructing and training an ulcerative colitis virtual biopsy model; and acquiring new clinical data of a patient with ulcerative colitis in real time, inputting the acquired new clinical data into the trained ulcerative colitis virtual biopsy model, and outputting a pathological grading result of ulcerative colitis through extraction and prediction of pathological features. According to the method, automatic analysis of image and endoscopic image features of the lesion area can be realized, the pathological activity state of the ulcerative colitis patient can be accurately judged, and association with long-term prognosis of the patient is established, so that help is provided for clinicians to formulate an individualized UC treatment scheme.
Resumen de: US2025154215A1
The present invention relates to a dual PRR-inhibiting peptide system consisting of TLR4- and RAGE-inhibiting motifs derived from S100A8 and S100A9 and conjugated with a CT peptide for colon-specific delivery. In human-derived monocyte THP-1 and mouse bone marrow-derived macrophages (BMDMs), S100A8/A9-derived peptides including TLR4 and RAGE-interacting motifs inhibit the binding of S100 to TLR4 or RAGE and the activation of the NLRP3 inflammasome in a dose-dependent manner. When the peptide according to the present invention is injected into mouse models of acute and chronic colitis, survival is significantly increased, and pathological damage to the colon is alleviated. In a mouse model of colitis-related colorectal cancer, when the peptide according to the present invention is injected, body weight is increased, tumor burden in the distal colon is decreased, and histological colon damage is significantly alleviated. When the peptide according to the present invention is injected into an oxaliplatin-resistant CRC xenograft mouse model, EMT-associated markers are reduced in tumor tissues and tumor growth is significantly inhibited.
Resumen de: US2025154591A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Resumen de: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Resumen de: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
Resumen de: CN119970806A
The invention provides application of Pseudomonas capilliformis (Pseudomonas capilliformis) to preparation of a medicine for preventing, treating and/or improving ulcerative colitis, and belongs to the technical field of probiotic preparations. The invention further provides a preparation method of the Pseudomonas capilliformis (Pseudomonas capilliformis) and application of the Pseudomonas capilliformis (Pseudomonas capilliformis (Pseudomonas capilliformis). In the invention, the pseudosciaena hirsuta is a beneficial bacterium screened through difference analysis of excrement samples in a clinical queue (including excrement samples of healthy control, active-stage ulcerative colitis patients and remission-stage ulcerative colitis patients). Existing commercialized probiotics mainly comprise lactobacillus, bifidobacterium and the like and are not designed for patients with ulcerative colitis, but the pseudomonas hirsuta provided by the invention better conforms to intestinal flora characteristics of the patients with ulcerative colitis and is suitable for individualized treatment of the patients with ulcerative colitis.
Resumen de: CN119991613A
The invention discloses a live pig digestive tract epidemic disease diagnosis method and system based on deep learning, and relates to the technical field of intelligent diagnosis of live pig digestive tract epidemic diseases. The six live pig digestive tract epidemic diseases including porcine epidemic diarrhea, porcine transmissible gastroenteritis, porcine proliferative bowel disease, piglet yellow scour, piglet white scour and piglet clostridial enteritis can be accurately identified. Firstly, a Mask RCNN is used for segmenting an image lesion area, the CNN is used for extracting features, then case information is fused, final disease classification is carried out through ML, and the recognition accuracy rate of 87.97% is achieved. Compared with an existing method, the method has the advantages that the diagnosis efficiency is improved, and the digital and intelligent development of live pig epidemic disease diagnosis is promoted.
Resumen de: CN119955922A
The invention discloses application of a biomarker in preparation of an inflammatory bowel disease screening or subtype detection product, the biomarker used for preparation of the inflammatory bowel disease screening product is GALNT14, and the biomarker used for the inflammatory bowel disease subtype detection product is MICAL2. The gene and/or protein expression level of the biomarker of the subject is analyzed on the basis of the logistic regression machine learning model, the biomarker can select different combinations, the detection accuracy is high, the specificity is good, the degree of injury to the subject is small, and the method is easy to accept; the method has a wide application prospect in clinical screening and subtype detection of inflammatory bowel diseases.
Resumen de: US2025146074A1
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
Resumen de: US2025146075A1
Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1 (PAI-1) inhibitor or tissue plasminogen activator (tPA).
Resumen de: US2025144219A1
The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.
Resumen de: CN119932179A
The invention provides a marker composition for evaluating the inflammatory enteritis treatment effect of mesenchymal stem cells and application of the marker composition, and relates to the technical field of biology. The marker composition is prepared from a Syt8 gene, a Gabrg2 gene, an Fpr1 gene and an Hs3st4 gene. The marker composition is applied to preparation of products for evaluating the treatment effect of inflammatory enteritis of subjects treated by mesenchymal stem cells, and the problem that in the prior art, a method for evaluating the treatment effect of IBD treated by the mesenchymal stem cells is lacked is solved.
Resumen de: WO2025089672A1
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Resumen de: WO2025089672A1
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Resumen de: WO2025089884A1
The present specification provides a method for providing information on ulcerative colitis by means of a processor, the method comprising: a step for receiving a Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) score for an individual; and a step for determining an inflammatory bowel disease prognosis for the individual on the basis of the received K-UCSQ score.
Resumen de: CN119896715A
The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating ulcerative colitis, which is characterized in that the traditional Chinese medicine composition is prepared by extracting the following raw medicinal materials in parts by weight: 5-15 parts of ginseng, 8-25 parts of cassia twig, 5-15 parts of nutmeg, 8-25 parts of poria cocos, 8-25 parts of roasted rhizoma atractylodis macrocephalae, 5-15 parts of rhizoma zingiberis, 10-30 parts of roasted semen coicis, 1-5 parts of indigo naturalis and 2-6 parts of coptis chinensis. According to the traditional Chinese medicine composition, ginseng, rhizoma atractylodis macrocephalae and poria cocos are used as monarch drugs together, and rhizoma atractylodis macrocephalae and poria cocos have the effects of replenishing qi to invigorate the spleen and eliminating dampness and excreting dampness together; semen coicis and rhizoma zingiberis are used as ministerial drugs and co-help the monarch drugs to resolve dampness and stop diarrhea; the traditional Chinese medicine composition has the functions of invigorating the spleen, replenishing qi, warming the kidney, stopping diarrhea, excreting dampness and removing toxicity, is mainly used for treating ulcerative colitis and irritable bowel syndrome (diarrhea type) clinically, can also be used for diagnosing'diarrhea 'and'stomachache' in traditional Chinese medicine, and can be used for treating
Resumen de: WO2025085928A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Nº publicación: WO2025085674A1 24/04/2025
Solicitante:
BACAINN THERAPEUTICS INC [US]
BACAINN THERAPEUTICS, INC
Resumen de: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
BOPI
Sede Electrónica
